{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:16:12Z","timestamp":1787015772980,"version":"build-2736575974"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":1739,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T00:00:00Z","timestamp":1616716800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The use of telmisartan (TEL), an angiotensin-receptor blocker, for the control of systemic hypertension and proteinuria in dogs has not been reported extensively in a clinical setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To determine the effects of an angiotensin-converting enzyme inhibitor (ACEi) alone, ACEi in combination with TEL, or TEL alone on systolic blood pressure and proteinuria in dogs with protein losing nephropathy (PLN).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Animals<\/jats:title>\n                    <jats:p>Forty-two client-owned dogs being treated for PLN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective observational study of medical records of dogs at a university teaching hospital from 2012 to 2018 with the use of benazepril or enalapril alone, TEL alone, or both modalities for the management of PLN. Noninvasive blood pressure and urine protein to creatinine ratio (UPC) were compared among the treatment groups over time. A multivariable mixed-effects linear regression model followed by post hoc analysis was used to estimate the marginal means and differences between the treatment groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In comparison to group ACEi alone, combination treatment of an ACEi with TEL significantly reduced (P = .007) systolic blood pressure by 13\u2009mm Hg (95% confidence interval [95% CI]: 4-22\u2009mm Hg). Angiotensin-converting enzyme inhibitor + TEL in comparison to ACEi alone showed significant (P = .01) reduction in UPC of 2.5 (95% CI: 0.6-4.4). The UPC of group ACEi + TEL was significantly lower (P = .01) in comparison to TEL alone by 3.8 (95% CI: 0.8-6.8).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Clinical Importance<\/jats:title>\n                    <jats:p>Telmisartan can be used to treat systemic hypertension and proteinuria in dogs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jvim.16102","type":"journal-article","created":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T05:19:13Z","timestamp":1616735953000},"page":"1231-1237","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Effect of telmisartan, angiotensin-converting enzyme inhibition, or both, on proteinuria and blood pressure in dogs"],"prefix":"10.1093","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6297-7181","authenticated-orcid":false,"given":"Brittany L.","family":"Fowler","sequence":"first","affiliation":[{"name":"University of Pennsylvania Matthew J. Ryan Veterinary Hospital , Philadelphia, Pennsylvania,","place":["USA"]},{"name":"Port City Veterinary Referral Hospital , Portsmouth, NH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darko","family":"Stefanovski","sequence":"additional","affiliation":[{"name":"University of Pennsylvania Matthew J. Ryan Veterinary Hospital , Philadelphia, Pennsylvania,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3134-1348","authenticated-orcid":false,"given":"Rebecka S.","family":"Hess","sequence":"additional","affiliation":[{"name":"University of Pennsylvania Matthew J. Ryan Veterinary Hospital , Philadelphia, Pennsylvania,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"McGonigle","sequence":"additional","affiliation":[{"name":"University of Pennsylvania Matthew J. Ryan Veterinary Hospital , Philadelphia, Pennsylvania,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,5,1]]},"reference":[{"key":"2026020303065211100_jvim16102-bib-0001","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/vr.162.5.141","article-title":"Associations between proteinuria, systemic hypertension and glomerular filtration rate in dogs with renal and non-renal disease","volume":"162","author":"Wehner","year":"2008","journal-title":"Vet Rec"},{"key":"2026020303065211100_jvim16102-bib-0002","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1939-1676.2005.tb02713.x","article-title":"Assessment and management of proteinuria in dogs and cats: 2004 ACVIM forum consensus statement (small animal). ACVIM Consensus Statement","volume":"19","author":"Lees","year":"2005","journal-title":"J Vet Intern Med"},{"key":"2026020303065211100_jvim16102-bib-0003","first-page":"1","article-title":"Evaluation of orally administered telmisartan for the reduction of indirect systolic arterial blood pressure in awake, clinically normal cats","volume":"21","author":"Coleman","year":"2018","journal-title":"J Feline Med Surg"},{"key":"2026020303065211100_jvim16102-bib-0004","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.jvc.2018.07.009","article-title":"Evaluation of the inhibitory effects of telmisartan on drug-induced renin-angiotensin-aldosterone system activation in normal dogs","volume":"20","author":"Konta","year":"2018","journal-title":"J Vet Cardiol"},{"key":"2026020303065211100_jvim16102-bib-0005","first-page":"464","article-title":"Angiotensin receptor blockers \u2013 advantages of the new sartans","volume":"61","author":"Sabbah","year":"2013","journal-title":"J Assoc Physicians India"},{"key":"2026020303065211100_jvim16102-bib-0006","first-page":"1","article-title":"Committee for Medicinal Products for Veterinary Use: CVMP assessment report for Semintra","author":"European Medicines Agency","year":"2012"},{"key":"2026020303065211100_jvim16102-bib-0007","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1111\/jvim.13639","article-title":"Comparison of efficacy of long-term oral treatment with telmisartan and benazepril in cats with chronic kidney disease","volume":"29","author":"Sent","year":"2015","journal-title":"J Vet Intern Med"},{"key":"2026020303065211100_jvim16102-bib-0008","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/jvim.15394","article-title":"Efficacy of long-term oral telmisartan treatment in cats with hypertension: results of a prospective European clinical trial","volume":"33","author":"Glaus","year":"2019","journal-title":"J Vet Intern Med"},{"key":"2026020303065211100_jvim16102-bib-0009","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/jvim.15429","article-title":"Safety and efficacy of orally administered telmisartan for the treatment of systemic hypertension in cats: results of a double-blind, placebo-controlled, randomized clinical trial","volume":"33","author":"Coleman","year":"2019","journal-title":"J Vet Intern Med"},{"key":"2026020303065211100_jvim16102-bib-0010","first-page":"1","article-title":"Antihypertensive treatment with telmisartan in a cat with amlodipine-induced gingival hyperplasia","volume":"3","author":"Desmet","year":"2017","journal-title":"J Feline Med Surg"},{"key":"2026020303065211100_jvim16102-bib-0011","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1177\/147323000102900210","article-title":"Effects of telmisartan on renal excretory function in conscious dogs","volume":"29","author":"Schierok","year":"2001","journal-title":"J Int Med Res"},{"key":"2026020303065211100_jvim16102-bib-0012","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1111\/jvim.12471","article-title":"Telmisartan treatment of refractory proteinuria in a dog","volume":"28","author":"Bugbee","year":"2014","journal-title":"J Vet Intern Med"},{"key":"2026020303065211100_jvim16102-bib-0013","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/BF03261834","article-title":"Comparison of hyperkalemic risk in hospitalized patients treated with different angiotensin receptor blockers","volume":"12","author":"Park","year":"2012","journal-title":"Am J Cardiovasc Drugs"},{"key":"2026020303065211100_jvim16102-bib-0014","first-page":"547","article-title":"A comparative study of the prevalence of hyperkalemia with the use of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers","volume":"5","author":"Sadjada","year":"2009","journal-title":"Ther Clin Risk Manag"},{"key":"2026020303065211100_jvim16102-bib-0015","article-title":"Computational Methods for Multilevel Modeling. Technical memorandum BL0112140-980226-01TM","author":"Bates","year":"1998"},{"key":"2026020303065211100_jvim16102-bib-0016","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1080\/00031305.1980.10483031","article-title":"Population marginal means in the linear model: an alternative to least squares means","volume":"34","author":"Searle","year":"1980","journal-title":"Am Stat"},{"key":"2026020303065211100_jvim16102-bib-0017","first-page":"S27","article-title":"The ICGSGS. Consensus recommendations for standard therapy of glomerular disease in dogs","volume":"27","author":"Brown","year":"2013","journal-title":"J Vet Intern Med"}],"container-title":["Journal of Veterinary Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvim.16102","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jvim.16102","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/35\/3\/1231\/66652820\/jvim16102.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/35\/3\/1231\/66652820\/jvim16102.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T08:07:19Z","timestamp":1770106039000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jvim\/article\/35\/3\/1231\/8447058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,1]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,5,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jvim.16102","relation":{},"ISSN":["1939-1676"],"issn-type":[{"value":"1939-1676","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,5]]},"published":{"date-parts":[[2021,5,1]]},"assertion":[{"value":"2020-05-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}